ArticleClinical rheumatology2026
Predicting the risk of bone erosion in rheumatoid arthritis using a SHAP-based interpretable machine learning model.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveBone erosion (BE) is a critical prognostic indicator in rheumatoid arthritis (RA). This study aimed to develop and validate an interpretable machine learning (ML) model for predicting BE risk in RA patients using the Shapley Additive exPlanations (SHAP) framework.
methodsThis multi-center retrospective study enrolled 412 RA patients without baseline BE. Patients were stratified into BE and non-bone erosion (NBE) groups confirmed by MRI or musculoskeletal ultrasound after a 2-year follow-up. After data preprocessing, including K-nearest neighbors imputation and synthetic minority over-sampling technique-based resampling to address class imbalance, least absolute shrinkage and selection operator regression was applied for feature selection. Ten ML algorithms were trained using fivefold cross-validation with GridSearchCV hyperparameter optimization. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration (Brier score), and decision curve analysis (DCA). For the optimal model, the SHAP framework was utilized to interpret both global and individual feature contributions.
resultsA total of 318 patients from Center 1 were randomly divided into a training set (n = 222) and an internal-test set (n = 96) at a 7:3 ratio. The 94 patients from Center 2 constituted an external-test set. The eXtreme Gradient Boosting (XGBoost) model demonstrated superior performance, achieving an AUC of 0.896 on the internal-test set and 0.893 on the external-test set. SHAP global analysis revealed that synovial Power Doppler Imaging (PDI) (mean SHAP value = 2.761), synovial hyperplasia (2.168), disease duration (1.359), and anti-cyclic citrullinated peptide (1.260) were the four most important predictors. DCA showed the XGBoost model provided net benefit across 10%-80% threshold probabilities.
conclusionThe SHAP-interpretable XGBoost model demonstrates strong discriminative performance in predicting BE risk in RA, highlighting synovial PDI and synovial hyperplasia as pivotal factors.
Indexed as
Identifiers
42481814What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.